2 results match your criteria: "Hartford Health Care and the Hospital of Central Connecticut[Affiliation]"
Cell Stress Chaperones
July 2020
Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT, 06269-3125, USA.
We present new data on the effects of HBOT on human kidney (HK-2) cell metabolism using a SeaHorse XF Analyzer to evaluate separately the state of mitochondrial and glycolytic energy metabolism. The data are discussed in the context of the concept of cellular caloristasis networks. The information on the changes in cellular energy metabolism stimulated by HBOT presented here provides new insights into the cellular energy state and mitochondrial environment in which sHSPs function.
View Article and Find Full Text PDFCell Stress Chaperones
November 2018
Department of Surgery, Hartford Health Care and the Hospital of Central Connecticut, Wound Care and Hyperbaric Medicine, New Britain, CT, 06050, USA.
Diabetic kidney disease (DKD) is the leading cause of end-stage renal failure in the western world. Current treatment of diabetic kidney disease relies on nutritional management and drug therapies to achieve metabolic control. Here, we discuss the potential application of hyperbaric oxygen therapy (HBOT) for the treatment of diabetic kidney disease (DKD), a treatment which requires patients to breathe in 100% oxygen at elevated ambient pressures.
View Article and Find Full Text PDF